Analyst Ratings For NASDAQ:ALNY – Alnylam Pharmaceuticals (NASDAQ:ALNY)
Today, Stifel Nicolaus lowered its price target on NASDAQ:ALNY – Alnylam Pharmaceuticals (NASDAQ:ALNY) to $95.00 per share.
Some recent analyst ratings include
- 4/2/2018-B. Riley Reiterated Rating of Buy.
- 4/2/2018-Jefferies Group Reiterated Rating of Buy.
- 3/28/2018-Evercore ISI initiated coverage with a In rating.
Recent Insider Trading Activity For NASDAQ:ALNY – Alnylam Pharmaceuticals (NASDAQ:ALNY)
NASDAQ:ALNY – Alnylam Pharmaceuticals (NASDAQ:ALNY) has insider ownership of 4.30% and institutional ownership of 92.12%.
- On 3/26/2018 Yvonne Greenstreet, COO, sold 7,221 with an average share price of $136.54 per share and the total transaction amounting to $985,955.34.
- On 3/20/2018 Laurie Keating, SVP, sold 1,562 with an average share price of $149.83 per share and the total transaction amounting to $234,034.46.
- On 3/14/2018 Akshay Vaishnaw, Insider, sold 88,554 with an average share price of $143.10 per share and the total transaction amounting to $12,672,077.40.
- On 3/14/2018 Barry E Greene, President, sold 38,460 with an average share price of $143.10 per share and the total transaction amounting to $5,503,626.00.
- On 3/13/2018 Laurie Keating, SVP, sold 20,000 with an average share price of $145.00 per share and the total transaction amounting to $2,900,000.00.
- On 3/13/2018 Paul Schimmel, Director, sold 27,823 with an average share price of $150.00 per share and the total transaction amounting to $4,173,450.00.
- On 3/9/2018 Philip A Sharp, Director, sold 15,000 with an average share price of $129.00 per share and the total transaction amounting to $1,935,000.00.
Recent Trading Activity for NASDAQ:ALNY – Alnylam Pharmaceuticals (NASDAQ:ALNY)
Shares of NASDAQ:ALNY – Alnylam Pharmaceuticals closed the previous trading session at 90.11 up +1.80 2.04% with 91.43499755859375 shares trading hands.